Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Marcie Tomblyn, MD, MS, Ryan Hillgruber, Taiga Nishihori, MD, Asmita Mishra, MD, Joseph Pidala, MD, MS, Ernesto Ayala, MD, Frederick L Locke, MD, Melissa Alsina, MD, Brian C. Betts, MD, Eric Padron, MD, Hugo F Fernandez, MD, Jeffrey E Lancet, MD, Alan List, MD, Rami S Komrokji, MD, Mohamed A. Kharfan-Dabaja, MD, Claudio Anasetti, MD

Blood (2013) 122 (21): 2152.

https://doi.org/10.1182/blood.V122.21.2152.2152

Published: 2013

Journal Articles

A Phase I/II Trial Evaluating The Use Of a Histone Deacetylase Inhibitor Panobinostat (LBH589) In Addition To Glucocorticoids In Patients With Acute Graft-Versus-Host Disease

Lia Perez, MD, Hugo F Fernandez, MD, Marcie Tomblyn, MD, MS, Frederick L Locke, MD, Teresa Field, MD, PhD, Joseph Pidala, MD, MS, Erika Elmer, CCRP, Francisca Beato, BS, Alejandro Villagra, PhD, Claudio Anasetti, MD

Blood (2013) 122 (21): 3308.

https://doi.org/10.1182/blood.V122.21.3308.3308

Published: 2013

Journal Articles

Autologous Transplantation in Relapsed and Refractory Mantle Cell Lymphoma

Bijal D. Shah, MD, Bryan J Little, MPH, Jennifer Cultrera, MD, Celeste M. Bello, MD, Lubomir Sokol, MD, Ph.D, Eduardo M. Sotomayor, MD, Marcie Tomblyn, MD, MS, Ernesto Ayala, MD

Blood (2012) 120 (21): 4542.

https://doi.org/10.1182/blood.V120.21.4542.4542

Published: 2012

Journal Articles

Cytarabine Either with Induction or Conditioning May Improve Outcomes Among Those Undergoing Autologous Transplantation in First or Second Remission for Mantle Cell Lymphoma

Bijal D. Shah, MD, Bryan J Little, MPH, Jennifer Cultrera, MD, Celeste M. Bello, MD, Lubomir Sokol, MD, Ph.D, Eduardo M. Sotomayor, MD, Marcie Tomblyn, MD, MS, Ernesto Ayala, MD

Blood (2012) 120 (21): 4546.

https://doi.org/10.1182/blood.V120.21.4546.4546

Published: 2012

Journal Articles

Clinicohistologic Assessment of Bone Marrow Engraftment In Patients with Hematologic Malignancies Received Double Umbilical Cord Blood Transplantation – A Single Institutional Observation

Deniz Peker, MD, Marcie Tomblyn, MD, MS, Taiga Nishihori, MD, Elizabeth M. Sagatys, MD, Kaaron Benson, MD, Xiaohui Zhang, Lynn Moscinski, MD, Ling Zhang, MD

Blood (2011) 118 (21): 4578.

https://doi.org/10.1182/blood.V118.21.4578.4578

Published: 2011

Journal Articles

Comparison of Sirolimus and Mycophenolate Mofetil As Salvage Treatment for Acute Graft-Versus-Host Disease

Taiga Nishihori, MD, Joseph Pidala, MD, MS, Jongphil Kim, PhD, Marcie Tomblyn, MD, MS, Claudio Anasetti, MD

Blood (2011) 118 (21): 4548.

https://doi.org/10.1182/blood.V118.21.4548.4548

Published: 2011

Journal Articles

Fludarabine and Targeted Busulfan Is Safe and Effective Conditioning Before Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in First Remission

Ghada M Kunter, MD, Janelle Perkins, PharmD, Lia Perez, MD, Joseph Pidala, MD, MS, Teresa Field, MD, PhD, Marcie Tomblyn, MD, MS, Hugo F. Fernandez, MD, Claudio Anasetti, MD

Blood (2011) 118 (21): 891.

https://doi.org/10.1182/blood.V118.21.891.891

Published: 2011

Journal Articles

Long Term Followup of Bystander Vaccine Therapy in Mantle Cell Lymphoma (MCL),

Bijal D. Shah, MD, Jianguo Tao, MD, PhD, Lubomir Sokol, MD, PhD, Paul A. Chervenick, MD, Marcie Tomblyn, MD, MS, Javier Pinilla-Ibarz, MD, PhD, Lynn Moscinski, MD, Scott Antonia, MD, Eduardo M. Sotomayor, Sophie Dessureault, MD

Blood (2011) 118 (21): 3720.

https://doi.org/10.1182/blood.V118.21.3720.3720

Published: 2011

Journal Articles

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

Joseph Pidala, MD, MS, Jongphil Kim, PhD, Heather Jim, PhD, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed A Kharfan-Dabaja, MD, Brian C. Betts, MD, Taiga Nishihori, MD, Mian Xu, William E. Janssen, PhD, Frederick L Locke, MD, Ernesto Ayala, MD, Lia Perez, MD, Janelle Perkins, PharmD, Teresa Field, MD, PhD, Leonel Ochoa, Melissa Alsina, MD, Claudio Anasetti, MD

Blood (2011) 118 (21): 323.

https://doi.org/10.1182/blood.V118.21.323.323

Published: 2011

Journal Articles

Randomized Phase III Trial of 131 iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)

Julie M Vose, MD, Shelly L Carter, ScD, Linda J Burns, MD, Ernesto Ayala, MD, Oliver W. Press, MD, PhD, Craig H. Moskowitz, MD, Edward A. Stadtmauer, MD, Shin Mineishi, MD, Richard F. Ambinder, Timothy S. Fenske, MD, Mary M. Horowitz, MD, Marcie Tomblyn, MD, MS

Blood (2011) 118 (21): 661.

https://doi.org/10.1182/blood.V118.21.661.661

Published: 2011

Journal Articles

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Mohamed A Kharfan-Dabaja, MD, Claudio Anasetti, MD, Nathalie Luis, B.S., Linda Brand, R.N., Janelle Perkins, PharmD, Hugo F. Fernandez, MD, Jose Leonel Ochoa-Bayona, M.D., Taiga Nishihori, MD, Lia E Perez, MD, Ernesto Ayala, MD, Javier Pinilla-Ibarz, MD, PhD, Lubomir Sokol, MD, PhD, Joseph Pidala, MD, MS, Frederick L Locke, MD, Eduardo M. Sotomayor, Teresa Field, MD, PhD, Marcie Tomblyn, MD, MS

Blood (2011) 118 (21): 3022.

https://doi.org/10.1182/blood.V118.21.3022.3022

Published: 2011

Journal Articles

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Taiga Nishihori, MD, Joseph Pidala, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed Kharfan-Dabaja, MD, Lia Perez, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Jose-Leonel ochoa-Bayona, M.D., Melissa Alsina, MD, Ernesto Ayala, MD, Jongphil Kim, Alan F. List, Claudio Anasetti, MD

Blood (2010) 116 (21): 2381.

https://doi.org/10.1182/blood.V116.21.2381.2381

Published: 2010

Journal Articles

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Teresa Field, MD, PhD, Janelle Perkins, PharmD, Taiga Nishihori, MD, Joseph Pidala, Hugo F. Fernandez, MD, Marcie Tomblyn, MD, MS, Mohamed Kharfan-Dabaja, MD, Lia Perez, MD, Rami S. Komrokji, MD, Jeffrey E. Lancet, MD, Jongphil Kim, Ernesto Ayala, MD, Melissa Alsina, MD, Jose-Leonel ochoa-Bayona, M.D., Alan F. List, Claudio Anasetti, MD

Blood (2010) 116 (21): 1333.

https://doi.org/10.1182/blood.V116.21.1333.1333

Published: 2010

Journal Articles

Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Janelle Perkins, PharmD, Teresa Field, MD, PhD, Jongphil Kim, PhD, Hugo F. Fernandez, MD, Lia Perez, MD, Ernesto Ayala, MD, Mohamed Kharfan-Dabaja, MD, Marcie Tomblyn, MD, MS, Daniel Sullivan, MD, Claudio Anasetti, MD

Blood (2010) 116 (21): 3499.

https://doi.org/10.1182/blood.V116.21.3499.3499

Published: 2010

Journal Articles

Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).

Blood (2010) 116 (21): 3481.

https://doi.org/10.1182/blood.V116.21.3481.3481

Published: 2010

Journal Articles

Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia.

Joseph A. Pidala, MD, Jongphil Kim, PhD, Claudio Anasetti, MD, Melissa Alsina, MD, Ernesto Ayala, MD, Teresa Field, MD, PhD, Mohamed A Kharfan-Dabaja, MD, Jose L Ochoa, MD, Lia Perez, MD, Janelle Perkins, PharmD, Marcie Tomblyn, MD, MS, Hugo F. Fernandez, MD

Blood (2009) 114 (22): 2290.

https://doi.org/10.1182/blood.V114.22.2290.2290

Published: 2009

Journal Articles

Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.

Paul Richardson, M.D., Marcie Tomblyn, MD, MS, Nancy Kernan, M.D., Joel A. Brochstein, MD, Shin Mineishi, MD, Amanda Termuhlen, MD, Sally Arai, MD, Stephan A. Grupp, MD, PhD, Eva Guinan, M.D., Paul L. Martin, MD, PhD, Selim Corbacioglu, MD, Ernst Holler, M.D., Ralph D'Agostino, Ph.D., Joseph Massaro, Ph.D., Alison L. Hannah, MD, Massimo Iacobelli, M.D., Robert J Soiffer, MD

Blood (2009) 114 (22): 654.

https://doi.org/10.1182/blood.V114.22.654.654

Published: 2009

Journal Articles

Comparison of Two Mycophenolate Mofetil Dosing Regimens Following Hematopoietic Cell Transplantation (HCT).

Pamala A. Jacobson, PharmD, Sheiren Farag El-Massah, John Rogosheske, PharmD, Amber Kerr, RN, Janel Boyle-Long, PharmD, Todd DeFor, MS, Cathryn Jennisen, PharmD, Claudio Brunstein, MD, John E. Wagner, MD, Marcie Tomblyn, MD, Daniel Weisdorf, MD

Blood (2008) 112 (11): 1116.

https://doi.org/10.1182/blood.V112.11.1116.1116

Published: 2008

Journal Articles

Decreased Infections in Recipients of Unrelated Donor (URD Hematopoietic Cell Transplantation (HCT) from Donors with An Activating KIR B Genotype (B/x)

Marcie Tomblyn, MD, MS, Jo-Anne Young, MD, Michael D Haagenson, MS, John P. Klein, PhD, Jan Storek, MD, PhD, Stephen Spellman, Sarah Cooley, MD, Daniel J. Weisdorf, MD, Jeffrey S. Miller, MD

Blood (2008) 112 (11): 351.

https://doi.org/10.1182/blood.V112.11.351.351

Published: 2008

Journal Articles

Encouraging Results of Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation for the Treatment of Advanced Lymphoid Malignancies.

Claudio G. Brunstein, MD, Susana Cantero, MD, Qing Cao, MS, Navneet Majhail, MD, Brian McClune, DO, Linda J. Burns, MD, Marcie Tomblyn, MD, Jeffrey S. Miller, MD, Bruce R. Blazar, MD, Philip B. McGlave, MD, Daniel J. Weisdorf, MD, John E. Wagner, MD

Blood (2007) 110 (11): 2028.

https://doi.org/10.1182/blood.V110.11.2028.2028

Published: 2007

NARROW

Evaluation Of Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes Of One Hundred Thirty-Two Patients With Myelodysplastic Syndrome (MDS) Or Chronic Myelomonocytic Leukemia (CMML) Up To Age Seventy-Five and The Effect Of Pre-Transplant 5-Azacitidine

A Phase I/II Trial Evaluating The Use Of a Histone Deacetylase Inhibitor Panobinostat (LBH589) In Addition To Glucocorticoids In Patients With Acute Graft-Versus-Host Disease

Autologous Transplantation in Relapsed and Refractory Mantle Cell Lymphoma

Cytarabine Either with Induction or Conditioning May Improve Outcomes Among Those Undergoing Autologous Transplantation in First or Second Remission for Mantle Cell Lymphoma

Clinicohistologic Assessment of Bone Marrow Engraftment In Patients with Hematologic Malignancies Received Double Umbilical Cord Blood Transplantation – A Single Institutional Observation

Comparison of Sirolimus and Mycophenolate Mofetil As Salvage Treatment for Acute Graft-Versus-Host Disease

Fludarabine and Targeted Busulfan Is Safe and Effective Conditioning Before Hematopoietic Stem Cell Transplantation in Adult Patients with Acute Lymphoblastic Leukemia in First Remission

Long Term Followup of Bystander Vaccine Therapy in Mantle Cell Lymphoma (MCL),

Sirolimus/Tacrolimus Facilitates Preferential Recovery of Regulatory T Cells (Treg) After Allogeneic Hematopoietic Cell Transplantation (HCT), and Is More Effective Than Methotrexate/Tacrolimus in Preventing Grade II-IV Acute Graft Vs. Host Disease (GVHD) and Moderate to Severe Chronic Gvhd

Randomized Phase III Trial of 131 iodine-Tositumomab (Bexxar)/Carmustine, Etoposide, Cytarabine, Melphalan (BEAM) Vs. Rituximab/BEAM and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma (DLBCL): No Difference in Progression-Free (PFS) or Overall Survival (OS)

Phase II Study of a Novel Reduced Toxicity Preparative Regimen for Hematopoietic Cell Allografting Combining Pentostatin (Nipent) and Targeted Doses of Intravenous Busulfan (Busulfex) with or without Rituximab (PB±R) Using a Novel Principle of CD4-Guided Immune Suppression

Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia In Patients up to Age 75: Comparison of Survival In Patients with An Available Donor Compared to Patients without a Donor

Prospective Trial of Pre-Transplant 5-Azacitidine on Hematopoietic Cell Transplantation Outcomes for Myelodysplastic Syndrome and CMML

Maximally Tolerated Busulfan Area Under the Concentration-Time Curve (AUC) In Combination with Fludarabine as Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation.

Meta-Analysis of Defibrotide (DF) In the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) with Comparison to a Historical Control (HC).

Targeted Intravenous Busulfan and Fludarabine Allogeneic Transplantation Conditioning in Acute Myeloid Leukemia.

Defibrotide (DF) in the Treatment of Severe Hepatic Veno-Occlusive Disease (VOD) with Multi-Organ Failure (MOF) Following Stem Cell Transplantation (SCT): Results of a Phase 3 Study Utilizing a Historical Control.

Comparison of Two Mycophenolate Mofetil Dosing Regimens Following Hematopoietic Cell Transplantation (HCT).

Decreased Infections in Recipients of Unrelated Donor (URD Hematopoietic Cell Transplantation (HCT) from Donors with An Activating KIR B Genotype (B/x)

Encouraging Results of Reduced Intensity Conditioning (RIC) Umbilical Cord Blood (UCB) Transplantation for the Treatment of Advanced Lymphoid Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only